CaPTC

Great shots from #SoAPCA25. We bring you highlights from one of our biggest events in 2025. #ViralMMSVideo #viral2026 #cancerresearch

Access to clinical trials shouldn’t be confusing or out of reach. In this episode of Men’s Health Matters, the conversation dives into ViRA, a powerful digital tool helping patients better understand research, navigate the process, and stay engaged. It’s a step forward in making healthcare more inclusive and equitable. Episode 4 is out now. #MensHealthMatters #HealthEquity #ProstateCancerAwareness #iCCaRE

💙🎗️ Calling All Prostate Cancer Survivors! 🎗️💙 Are you ready to turn your lived experience into advocacy and meaningful impact? The iCCaRE Prostate Cancer Advocacy Training Program is now accepting interest forms for our upcoming training: 📍 In-Person | Jacksonville, FL (Mayo Clinic) 📅 April 13, 2026 (Training will be followed by participation in the iCCaRE Prostate Cancer Scientific Symposium.) This is a fully funded opportunity for prostate cancer survivors. ✅ No cost to participate ✅ Travel support available (for in-person participants) ✅ Accommodation and meals provided (as applicable) ✅ Certificate of Completion awarded ✅ Optional virtual participation available for selected individuals Selected participants will receive full support to attend and complete the 1-day advocacy training on April 13. Participants will also have the opportunity to take part in the iCCaRE Prostate Cancer Scientific Symposium, gaining direct exposure to current research, community engagement efforts, and advocacy leadership. In-person spots are limited (15 participants; first come, first served). A limited number of virtual participation opportunities will also be offered to selected individuals. If you, or someone you know, is a prostate cancer survivor interested in becoming a certified prostate cancer advocate, we encourage you to complete the interest form today. Your voice matters. Your experience matters. Join us in advancing equitable prostate cancer advocacy. 💙 Complete the form here: surveys.mayoclinic.org/jfe/form/SV_0u… #ProstateCancerSurvivor #CancerAdvocacy #iCCaRE #HealthEquity #ProstateCancerAwarenes

📣 Call for Applications - Cohort 2 - 8 more days! The iCCaRE Consortium is now accepting applications for the Global Oncology Certificate Program. 🗓 Applications open March 2nd – March 20th, 2026 🎓 Fully funded 🌍 Open to pre-doctoral students and students in health-related Master’s or PhD programs worldwide This program prepares future leaders in cancer prevention, control, and survivorship through global oncology training and research mentorship. 📩 Apply today or share with someone who should! #GlobalOncology #CancerResearch #HealthEquity #iCCaRE

recognition and wish her great success in this critical assignment that will significantly advance cancer prevention and control efforts in Nigeria.

the National Strategic Cancer Control Plan, aligning National efforts toward reducing cancer incidence, improving access to quality care, and strengthening cancer research and policy development in Nigeria. We congratulate Professor Odedina on this well-deserved National

We at CaPTC wish every woman embodying the true realities of womanhood, a happy international women's day. Thank you for being epitomes of tenderness. Your strength is admirable & with you, the world is a brighter place. Thank you for living 🤍🌹 #InternationalWomensDay2026

Today, we bring the message of hope to everyone living with cancer and particularly, prostate cancer. You've got what it takes to Fight! Fight!! Fight!!! Check out the educative theme song below sharing a vital message about prostate cancer👇👇👇 youtu.be/Cp4XhEzB2RI?si…

📣 Call for Applications - Cohort 2 The iCCaRE Consortium is now accepting applications for the Global Oncology Certificate Program. 📷 Applications open March 2 – March 20, 2026 @cathbadejo1 @DrOdedina @CaPTC7 @iCCaREMedia @FUNAAB_SUG

🚨 Now Accepting Applications: Early Career Investigator Stimulus Award (ECISA) U.S. Investigators Are you an early-career investigator conducting research in prostate cancer? The iCCaRE Consortium is proud to support the next generation of researchers advancing innovation in etiology, prevention, detection, diagnosis, treatment, and survivorship. 🔬 Award Details: • Up to $5,000 per project • Two awards granted annually • 1-year funding period (Sept 1 – Aug 31) • Collaboration across iCCaRE sites encouraged 📅 Submission Deadline: February 28, 2026 (Midnight EST) If you are affiliated with an iCCaRE U.S. institution and are within 10 years of your terminal degree, we encourage you to apply. Scan the QR code to submit your application and take the next step in advancing impactful prostate cancer research. #iCCaRE #ProstateCancerResearch #EarlyCareerInvestigator #HealthEquity #CancerResearch #AcademicMedicine

Two patients reminded me why we do this work. One completing treatment with grace. Another reclaiming her identity as she returns to work. #Cancercontrol is also about people thriving & returning to the lives they love. → tinyurl.com/PatientInspira… #KeepingAbreastWithDrMiriam

🎉 Congratulations to iCCaRE MPIs, Dr. Che Ngufor and Dr. Folakemi Odedina! 🎉 We are proud to celebrate Dr. Che Ngufor, PhD and Dr. Folakemi Odedina, PhD,  both iCCaRE MPIs, on their selection for the Mayo Clinic Center for Digital Health’s Artificial Intelligence/Machine Learning Enablement Award, in partnership with the Office of Health Equity and Inclusion. Their iCCaRE project “Deploying ViRA: Building Mayo Clinic’s First Cloud-Streamed XR Infrastructure for Equitable Cancer Care and Clinical Innovation” is one of five projects funded through this highly competitive program, made possible by the generous support of Dalio Philanthropies. Each selected project will receive $100,000 in 2026 to advance its work. This award supports projects that thoughtfully integrate AI and machine learning into clinical practice to reduce bias, strengthen trust, and expand equitable solutions for patients and staff. ViRA (Virtual Reality Assistant) exemplifies this mission by using AI and immersive virtual reality to deliver personalized, culturally tailored psychosocial cancer support, particularly for communities disproportionately affected by prostate cancer. By matching patients’ emotional and social needs with survivor stories, counseling, and community resources delivered via cloud-streamed XR, web-based platforms, and community kiosks the team aims to improve patient understanding, reduce distress, and create ascalable, fair, and inclusive model for AI-enabled cancer care at Mayo Clinic and beyond. 👏 Congratulations to Drs. Ngufor and Odedina and the entire project team on this impactful achievement!

📍Nigeria Here, take a peep into CaPTC's participation in #WorldCancerDay 🌎 2026 in #Abuja. Video shows moments with @DrOdedina. #ResearchInAfrica #AbujaTwitterCommunity #GlobalHealth #SciencelnAction #PublicHealthImpact #BuildingTheFuture

as we continue to actively & aggressively create access to better & affordable care by pushing laudable initiatives that break barriers. Governments & institutions globally are also urged to become increasingly involved in battling this menace. Every life matters & we can win!

Happy #WorldCancerDay We @CaPTC7 remain fixated on our long term vision of easing the burden of #ProstateCancer disparities & through this, we continue to contribute our quota to ensuring that everyone has a chance. To everyone who's fighting cancer today, we stand with you

🤍

West Africa and beyond. Thank you, Professor Popoola @Ademolap for your outstanding research contributions and dedication to CaPTC.

He co-authored CaPTC's whole exome sequencing study of Nigerian prostate tumors, a landmark step in understanding ancestry linked DNA repair gene mutations in prostate cancer. Professor Popoola continues to advance research that strengthens both science and clinical care across

Investigator Spotlight Professor Ademola Popoola is a leader in urology and prostate cancer research and a Principal Investigator with CaPTC. His work spans clinical urology, genomic research, and studies on prostate cancer risk and survivorship in men of African ancestry.